Stop the presses! The OCEANIC-AF research study has been halted! This stage III research study was looking into asundexian compared to apixaban in clients at risk for stroke, and the decision was made to stop it early because of the inferior effectiveness of asundexian compared to the control arm. Bayer will be diving into the data further to understand the impact and release the information. Stay tuned for updates!
But don’t worry, the OCEANIC-STROKE stage III study will continue as planned, so there’s still hope for progress in this area. However, there is some concern that patients may not have suitable treatment options, so these developments are critical to address.
Asundexian is still on the investigational list, meaning it has not been approved for any indication in any country. The OCEANIC Program, which includes the OCEANIC-AF, OCEANIC-STROKE, and OCEANIC-AFINA studies, is designed to explore the potential benefits of asundexian for patients at risk of stroke. The fate of OCEANIC-AFINA will also be re-evaluated, so stay tuned for what’s to come!
If you want to read more about this breaking news, head over to Bayer’s website for the full story. Stay informed!
